{"id":295738,"date":"2026-05-16T07:28:13","date_gmt":"2026-05-16T07:28:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-tx\/295738\/"},"modified":"2026-05-16T07:28:13","modified_gmt":"2026-05-16T07:28:13","slug":"houston-methodist-researchers-identify-b-cells-as-driver-of-immunotherapy-resistance-in-liver-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-tx\/295738\/","title":{"rendered":"Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer"},"content":{"rendered":"\n<p class=\"has-drop-cap\">Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.\u00a0<\/p>\n<p>New research led by investigators now at Houston Methodist Hospital suggests an unexpected immune cell population\u2014tumor-associated B cells\u2014may be a key driver of resistance and a promising therapeutic target.<\/p>\n<p>The study shows that B cells infiltrating liver tumors can suppress T cells\u2019 anti-tumor activity, limiting the effectiveness of immunotherapy.<\/p>\n<p>In preclinical models, selectively disrupting this B-cell-mediated immunosuppression significantly enhanced the activity of both immune checkpoint blockade and STING-based immune therapies.<\/p>\n<p>The findings highlight a previously underappreciated component of the liver tumor microenvironment and suggest new combination strategies that could expand the reach of immunotherapy for patients with advanced liver cancer.<\/p>\n<p>An immune paradox inside liver tumors<\/p>\n<p>Immune checkpoint blockade (ICB) therapies, such as PD-1 and PD-L1 inhibitors, work primarily by reinvigorating cytotoxic\u00a0<\/p>\n<p>T cells that recognize and destroy tumor cells. In hepatocellular carcinoma, these therapies\u2014often combined with anti-angiogenic drugs\u2014have transformed systemic treatment options in recent years.<\/p>\n<p>New research led by investigators now at Houston Methodist Hospital suggests an unexpected immune cell population\u2014tumor-associated B cells\u2014may be a key driver of resistance and a promising therapeutic target.\u00a0<\/p>\n<p>Yet clinical response rates remain modest. More than 70% of patients with advanced HCC ultimately fail to respond or develop resistance to ICB therapies.<\/p>\n<p>Most research into this resistance has focused on T cells and other well-known immune suppressors such as regulatory T cells or myeloid-derived suppressor cells. However, the new study reveals that B lymphocytes\u2014traditionally known for producing antibodies\u2014can also play a powerful regulatory role inside tumors.<\/p>\n<p>By analyzing multiple RNA sequencing datasets from liver cancer models treated with immunotherapy, researchers found that immune checkpoint blockade consistently increased infiltration of both CD8+ T cells and B cells within tumors. While the T-cell expansion was expected, the rise in B cells was more surprising.<\/p>\n<p>Further investigation showed that many of these infiltrating B cells adopted an immunosuppressive phenotype, releasing anti-inflammatory cytokines such as IL-10 that dampen anti-tumor immunity.<\/p>\n<p>Playing for the wrong side<\/p>\n<p>Using mouse models that mimic human HCC\u2014including tumors arising in fibrotic liver tissue\u2014investigators demonstrated that immunotherapy and STING agonists both trigger an influx of B cells into tumors.<\/p>\n<p>These B cells often organized into clusters resembling tertiary lymphoid structures, immune aggregates sometimes seen in chronic inflammatory diseases and cancers. But in this context, the B-cell populations appeared to limit therapeutic responses.<\/p>\n<p>When researchers experimentally depleted B cells, the results were striking.<\/p>\n<p>Combining B-cell depletion with immune checkpoint blockade significantly delayed tumor growth and improved survival compared with immunotherapy alone. Similar results were observed when B-cell depletion was paired with activation of the STING pathway\u2014an innate immune signaling mechanism that stimulates type I interferon responses and is being explored as an anticancer strategy.<\/p>\n<p>A new immune checkpoint on B cells<\/p>\n<p>The researchers also identified a potential molecular target driving this immunosuppressive B-cell activity.<\/p>\n<p>The work highlights TIM-1, an immune checkpoint receptor expressed on a subset of regulatory B cells. Tumors treated with immunotherapy or STING agonists showed increased expression of TIM-1 and higher levels of regulatory cytokines associated with immune suppression.<\/p>\n<p>Blocking TIM-1 signaling alongside STING activation produced stronger anti-tumor responses than either therapy alone, enhancing CD8+ T-cell activity and slowing tumor progression in immunotherapy-resistant models.<\/p>\n<p>The results suggest that TIM-1 could serve as both a biomarker of resistance and a therapeutic target.<\/p>\n<p>Expanding the immunotherapy playbook<\/p>\n<p>Importantly, B-cell targeting alone did not affect tumor growth, indicating that these cells become therapeutically relevant primarily in the context of immune activation.<\/p>\n<p>But when combined with checkpoint blockade and innate immune stimulation, removing B-cell-mediated suppression dramatically amplified treatment responses. In some models, a multi-drug combination of STING activation, checkpoint inhibition and B-cell targeting eradicated tumors entirely and generated durable immune memory.<\/p>\n<p>The findings add to a growing body of evidence that tumor microenvironments\u2014not just cancer cells themselves\u2014determine how patients respond to immunotherapy.<\/p>\n<p>The study also found that gene signatures associated with TIM-1-positive B cells correlated with survival in human liver cancer datasets, suggesting that the mechanisms observed in mice may be clinically relevant.<\/p>\n<p>The findings add to a growing body of evidence that tumor microenvironments\u2014not just cancer cells themselves\u2014determine how patients respond to immunotherapy.<\/p>\n<p>While B cells can play beneficial roles in many cancers by presenting antigens and supporting immune activation, this work demonstrates that specific B-cell subsets may instead promote immune escape in liver cancer.<\/p>\n<p>The implication for clinicians and researchers: Targeting immunosuppressive B cells\u2014or selectively reprogramming them\u2014could help unlock more durable responses for patients with this challenging disease.<\/p>\n","protected":false},"excerpt":{"rendered":"Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.\u00a0&hellip;\n","protected":false},"author":2,"featured_media":295739,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[56,58,57],"class_list":["post-295738","post","type-post","status-publish","format-standard","has-post-thumbnail","category-houston","tag-houston","tag-houston-headlines","tag-houston-news"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/295738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=295738"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/295738\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/295739"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=295738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=295738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=295738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}